Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression
- PMID: 35646347
- PMCID: PMC9130847
- DOI: 10.1177/20499361221095831
Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression
Abstract
Tuberculosis is one of the leading causes of death worldwide, primarily affecting low- and middle income countries and individuals with limited-resources within fractured health care systems. Unfortunately, the COVID-19 pandemic has only served to aggravate the already existing diagnostic gap, decreasing the number of people who get diagnosed and thereby complete successful treatment. In addition to this, comorbidities act as an external component that when added to the TB management equation, renders it even more complex. Among the various comorbidities that interact with TB disease, diabetes mellitus and depression are two of the most prevalent among non-communicable diseases within the TB population and merits a thoughtful consideration when the healthcare system provides care for them. TB patients with diabetes mellitus (TB-DM) or depression both have an increased risk of mortality, relapse and recurrence. Both of these diseases when in presence of TB present a 'vicious-circle-like' mechanism, meaning that the effect of each disease can negatively add up, in a synergistic manner, complicating the patient's health state. Among TB-DM patients, high glucose blood levels can decrease the effectiveness of anti-tuberculosis drugs; however, higher doses of anti-tuberculous drugs could potentially decrease the effects of DM drugs. Among the TB-depression patients, not only do we have the adherence to treatment problems, but depression itself can biologically shift the immunological profile responsible for TB containment, and the other way around, TB itself can alter the hormonal balance of several neurotransmitters responsible for depression. In this paper, we review these and other important aspects such as the pharmacological interactions found in the treatment of TB-DM and TB-depression patients and the implication on TB care and pharmacological considerations.
Keywords: comorbidities; depression; diabetes; therapy; tuberculosis.
© The Author(s), 2022.
Conflict of interest statement
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References
-
- Global tuberculosis report 2021 . Geneva: World Health Organization, 2021.
-
- Fløe A, Hilberg O, Wejse C, et al.. Comorbidities, mortality and causes of death among patients with tuberculosis in Denmark1998-2010: a nationwide, register-based case-control study. Thorax 2018; 73: 70–77. - PubMed
-
- Swaminathan S, Ramachandran R, Baskaran G, et al.. Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 2000; 4: 839–844, https://www.ncbi.nlm.nih.gov/pubmed/10985652 - PubMed
-
- Ugarte-Gil C, Curisinche M, Herrrera-Flores E, et al.. Situación de la comorbilidad tuberculosis y diabetes en personas adultas en el Perú, 2016-2018. Rev Peru Med Exp Salud Publica 2021; 38: 254–260, https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/6764 (accessed 1 December 2021). - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
